| Literature DB >> 32867672 |
Elaheh Emadi1, Fatemeh Akhoundi2, Seyed Mehdi Kalantar1, Modjtaba Emadi-Baygi3,4.
Abstract
BACKGROUND: The Human Leukocyte Antigen G (HLA-G) protein is an immune tolerogenic molecule with 7 isoforms. The change of expression level and some polymorphisms of the HLA-G gene are involved in various pathologies. Therefore, this study aimed to predict the most deleterious missense non-synonymous single nucleotide polymorphisms (nsSNPs) in HLA-G isoforms via in silico analyses and to examine structural and functional effects of the predicted nsSNPs on HLA-G isoforms.Entities:
Keywords: Deleterious SNPs; HLA-G gene; In silico analysis; Missense mutation; Structural and functional impact
Mesh:
Substances:
Year: 2020 PMID: 32867672 PMCID: PMC7457528 DOI: 10.1186/s12863-020-00890-y
Source DB: PubMed Journal: BMC Genet ISSN: 1471-2156 Impact factor: 2.797
Fig. 1HLA-G heavy chain gene comprises 7 introns (i1-i7) and 8 exons (each with a distinctive color) with an internal stop codon in Exon 6. As shown in figure each exon encodes a discrete part of the heavy chain, except exon 7 and 8. Alternative splicing events of HLA-G primary transcript (exclusion exon 3 or/and exon 4 and keeping of intron 4 or intron 2 from the final gene transcript) generate seven isoforms. Soluble isoforms lack the transmembrane and cytoplasmic regions due to the intron retention, which includes an immature stop codon. HLA-G5 and HLA-G6 have a tail (21 amino acids) that plays a role in their solubility. HLA-G1 is the complete molecule. HLAG1 is homologous to HLA-G5 and both of them associate with B2M. The signal peptide (exon 1) and α1 domain (exon 2) are existing in all isoforms. Figure modified from Bainbridge et al. [14]
Fig. 2Flowchart of the different steps of the study
Fig. 3The 3-D pie-chart shows the percentage of missense SNPs, 5′ UTR, 3′ UTR and other types of SNPs in HLA-G gene (according to the dbSNP database on December 2018)
SNPs analyzed in isoform 1by SIFT, PROVEAN, Polyphen 2.0, I-mutant 3.0, SNPs&GO
| Isoform 1 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prediction | Score | Prediction | Score | Prediction | Score | SVM3 Prediction Effect | DDG Value | Prediction | ||||
| rs17851921 | CAC ⇒ CCC | H117P | DAMAGING | 0 | Deleterious | 9.043 | Probably damaging | 1.000 | Large Increase | 0.33 | Disease | 0.805 |
| CAC ⇒ CTC | H117L | Deleterious | 9.930 | Probably damaging | 1.000 | Large Increase | 0.65 | Disease | 0.794 | |||
| rs111233577 | CTG ⇒ CGG | L290R | DAMAGING | 0 | Deleterious | 3.802 | Probably damaging | 1.000 | Large Decrease | -1.44 | Disease | 0.786 |
| rs142596947 | CCT ⇒ ACT | P234T | DAMAGING | 0 | Deleterious | 5.194 | Probably damaging | 0.991 | Large Decrease | -1.08 | Disease | 0.557 |
| rs144577485 | CCC ⇒ GCC | P209A | DAMAGING | 0 | Deleterious | 5.495 | Possibly damaging | 0.774 | Large Decrease | -0.99 | Disease | 0.575 |
| rs145097667 | CAT ⇒ TAT | H287Y | DAMAGING | 0 | Deleterious | 3.810 | Probably damaging | 0.999 | Large Increase | 0.54 | Disease | 0.743 |
| rs572025435 | AGG ⇒ AGT | R30S | DAMAGING | 0 | Deleterious | 3.653 | Probably damaging | 0.991 | Large Decrease | -1.17 | Disease | 0.542 |
| rs748013931 | ACC ⇒ CCC | T158P | DAMAGING | 0 | Deleterious | 5.173 | Probably damaging | 1.000 | Large Decrease | -0.52 | Disease | 0.696 |
| rs749006959 | TAT ⇒ TGT | Y142C | DAMAGING | 0 | Deleterious | 8.189 | Probably damaging | 1.000 | Large Increase | -1.13 | Disease | 0.749 |
| rs750238738 | ATC ⇒ TTC | I237F | DAMAGING | 0 | Deleterious | 2.554 | Probably damaging | 0.993 | Large Decrease | -1.46 | Disease | 0.777 |
| rs756652306 | GTG ⇒ GCG | V285A | DAMAGING | 0 | Deleterious | 2.527 | Probably damaging | 0.998 | Large Decrease | -1.04 | Disease | 0.617 |
| rs760500349 | CAG ⇒ CTG | Q266L | DAMAGING | 0.04 | Deleterious | 4.451 | Probably damaging | 1.000 | Large Increase | 0.19 | Disease | 0.706 |
| rs763201540 | GAC ⇒ AAC | D53N | DAMAGING | 0 | Deleterious | 3.842 | Probably damaging | 1.000 | Large Decrease | -1.07 | Disease | 0.728 |
| GAC ⇒ TAC | D53Y | Deleterious | 6.941 | Probably damaging | 1.000 | Large Decrease | -0.29 | Disease | 0.872 | |||
| rs765275727 | TGG ⇒ CGG | W298R | DAMAGING | 0 | Deleterious | 8.828 | Probably damaging | 1.000 | Large Decrease | -0.8 | Disease | 0.713 |
| rs770027530 | TGC ⇒ TAC | C227Y | DAMAGING | 0 | Deleterious | 7.461 | Probably damaging | 1.000 | Large Decrease | -0.12 | Disease | 0.854 |
| TGC ⇒ TTC | C227F | Deleterious | 7.461 | Probably damaging | 1.000 | Large Decrease | 0.06 | Disease | 0.882 | |||
| rs770412396 | CTG ⇒ CCG | L102P | DAMAGING | 0.01 | Deleterious | 6.187 | Probably damaging | 1.000 | Large Decrease | -1.63 | Disease | 0.786 |
| rs772834879 | TAC ⇒ CAC | Y142H | DAMAGING | 0 | Deleterious | -4.54 | Probably damaging | 1.000 | Large Decrease | -1.31 | Disease | 0.635 |
| rs780697086 | TGC ⇒ AGC | C188S | DAMAGING | 0 | Deleterious | -8.51 | Probably damaging | 0.975 | Large Decrease | -0.8 | Disease | 0.768 |
| rs781774818 | CCT ⇒ CAT | P259H | DAMAGING | 0 | Deleterious | 5.764 | Probably damaging | 1.000 | Large Decrease | -1.22 | Disease | 0.581 |
| rs867319917 | TGG ⇒ CGG | W157R | DAMAGING | 0 | Deleterious | 12.658 | Probably damaging | 1.000 | Large Decrease | -0.86 | Disease | 0.791 |
| rs1200732770 | GCC ⇒ GAC | A229D | DAMAGING | 0 | Deleterious | 4.021 | Probably damaging | 1.000 | Large Decrease | -0.87 | Disease | 0.775 |
| rs1260086927 | CAG ⇒ CCG | Q96P | DAMAGING | 0.01 | Deleterious | 4.891 | Probably damaging | 0.996 | Large Decrease | -0.4 | Disease | 0.524 |
| rs1265409678 | CTC ⇒ CGC | L294R | DAMAGING | 0.01 | Deleterious | 3.443 | Probably damaging | 0.999 | Large Decrease | -1.31 | Disease | 0.664 |
| rs1317292772 | GAT ⇒ AAT | D143N | DAMAGING | 0 | Deleterious | 4.485 | Probably damaging | 0.996 | Large Decrease | -0.55 | Disease | 0.662 |
| GAT ⇒ CAT | D143H | Deleterious | 6.283 | Possibly damaging | 0.725 | Large Decrease | -0.24 | Disease | 0.643 | |||
| rs1379742188 | CGC ⇒ AGC | R205S | DAMAGING | 0.02 | Deleterious | 4.275 | Possibly damaging | 0.939 | Large Decrease | -1.2 | Disease | 0.640 |
| rs1390270595 | TAC ⇒ TGC | Y51C | DAMAGING | 0.03 | Deleterious | 6.756 | Probably damaging | 1.000 | Large Decrease | -1.29 | Disease | 0.724 |
| rs1397132797 | CTG ⇒ CCG | L196P | DAMAGING | 0.01 | Deleterious | 5.562 | Probably damaging | 1.000 | Large Decrease | -1.66 | Disease | 0.760 |
| rs1414848134 | GAC ⇒ GTC | D54V | DAMAGING | 0 | Deleterious | 6.752 | Possibly damaging | 0.893 | Large Decrease | -1.04 | Disease | 0.874 |
| rs143056505 | CCT ⇒ CTT | P234L | DAMAGING | 0 | Deleterious | 6.497 | Possibly damaging | 0.454 | Large Decrease | -0.33 | Disease | 0.711 |
| rs147253884 | CCC ⇒ CGC | P209R | DAMAGING | 0 | Deleterious | 6.191 | Probably damaging | 0.993 | Large Decrease | -0.61 | Disease | 0.763 |
| rs1475659109 | CCC ⇒ CTC | P39L | DAMAGING | 0 | Deleterious | 7.485 | Probably damaging | 1.000 | Large Increase | -0.48 | Disease | 0.582 |
| rs555347515 | ATG ⇒ AAG | M29K | DAMAGING | 0 | Deleterious | 3.427 | Probably damaging | 0.996 | Large Decrease | -1.48 | Disease | 0.774 |
| rs556645753 | GAC ⇒ GGC | D153G | DAMAGING | 0 | Deleterious | 6.309 | Probably damaging | 0.999 | Large Decrease | -0.73 | Disease | 0.511 |
| rs565858069 | GAC ⇒ CAC | D130H | DAMAGING | 0.03 | Deleterious | 5.927 | Probably damaging | 1.000 | Large Decrease | -0.49 | Disease | 0.648 |
| rs754527717 | GAT ⇒ GGT | D244G | DAMAGING | 0.01 | Deleterious | 3.915 | Probably damaging | 0.995 | Large Decrease | -0.09 | Disease | 0.561 |
| rs1161818149 | CTG ⇒ CAG | L105Q | DAMAGING | 0 | Deleterious | 4.572 | Probably damaging | 1.000 | Large Decrease | -2.04 | Disease | 0.764 |
| CTG ⇒ CCG | L105P | Deleterious | 5.349 | Probably damaging | 1.000 | Large Decrease | -1.69 | Disease | 0.799 | |||
SNPs analyzed in isoform 1by PhD-SNP, SNAP2, Mupro
| Isoform 1 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| SNP rsID | Codons | Substitution | PhD-SNP | SNAP2 | MUpro | ||||
| Prediction | Score | Prediction | Score | Expected Accuracy | Prediction | DDG Value | |||
| rs17851921 | CAC ⇒ CCC | H117P | Disease | 5 | effect | 94 | 95% | DECREASE | -0.94483558 |
| CAC ⇒ CTC | H117L | Disease | 5 | effect | 82 | 91% | INCREASE | 0.17248775 | |
| rs111233577 | CTG ⇒ CGG | L290R | Disease | 6 | effect | 52 | 75% | DECREASE | -1.4553025 |
| rs142596947 | CCT ⇒ ACT | P234T | Disease | 8 | effect | 58 | 75% | DECREASE | -0.8378542 |
| rs144577485 | CCC ⇒ GCC | P209A | Disease | 4 | effect | 30 | 66% | DECREASE | -1.3457662 |
| rs145097667 | CAT ⇒ TAT | H287Y | Disease | 6 | effect | 79 | 85% | INCREASE | 0.00175126 |
| rs572025435 | AGG ⇒ AGT | R30S | Disease | 4 | effect | 2 | 53% | DECREASE | -1.582361 |
| rs748013931 | ACC ⇒ CCC | T158P | Disease | 3 | effect | 56 | 75% | DECREASE | -1.0769639 |
| rs749006959 | TAT ⇒ TGT | Y142C | Disease | 7 | effect | 69 | 80% | DECREASE | -1.7925753 |
| rs750238738 | ATC ⇒ TTC | I237F | Disease | 5 | effect | 45 | 71% | DECREASE | -0.97093071 |
| rs756652306 | GTG ⇒ GCG | V285A | Disease | 1 | effect | 36 | 66% | DECREASE | -0.89978472 |
| rs760500349 | CAG ⇒ CTG | Q266L | Disease | 6 | effect | 78 | 85% | DECREASE | -0.05227910 |
| rs763201540 | GAC ⇒ AAC | D53N | Disease | 5 | effect | 52 | 75% | DECREASE | -0.79149414 |
| GAC ⇒ TAC | D53Y | Disease | 9 | effect | 84 | 91% | DECREASE | -0.45294328 | |
| rs765275727 | TGG ⇒ CGG | W298R | Disease | 5 | effect | 87 | 91% | DECREASE | -1.1870648 |
| rs770027530 | TGC ⇒ TAC | C227Y | Disease | 8 | effect | 68 | 80% | DECREASE | -0.88892871 |
| TGC ⇒ TTC | C227F | Disease | 9 | effect | 75 | 85% | DECREASE | -0.71910267 | |
| rs770412396 | CTG ⇒ CCG | L102P | Disease | 7 | effect | 79 | 85% | DECREASE | -2.238046 |
| rs772834879 | TAC ⇒ CAC | Y142H | Disease | 5 | effect | 72 | 85% | DECREASE | -2.1531554 |
| rs780697086 | TGC ⇒ AGC | C188S | Disease | 4 | effect | 75 | 85% | DECREASE | -1.0332928 |
| rs781774818 | CCT ⇒ CAT | P259H | Disease | 5 | effect | 4 | 53% | DECREASE | -1.1893017 |
| rs867319917 | TGG ⇒ CGG | W157R | Disease | 3 | effect | 93 | 95% | DECREASE | -0.91293557 |
| rs1200732770 | GCC ⇒ GAC | A229D | Disease | 8 | effect | 75 | 85% | DECREASE | -0.6414612 |
| rs1260086927 | CAG ⇒ CCG | Q96P | Disease | 6 | effect | 43 | 71% | DECREASE | -0.97929591 |
| rs1265409678 | CTC ⇒ CGC | L294R | Disease | 6 | effect | 57 | 75% | DECREASE | -1.0427076 |
| rs1317292772 | GAT ⇒ AAT | D143N | Disease | 4 | effect | 22 | 63% | DECREASE | -1.2006322 |
| GAT ⇒ CAT | D143H | Disease | 9 | effect | 25 | 63% | DECREASE | -1.2840175 | |
| rs1379742188 | CGC ⇒ AGC | R205S | Disease | 5 | effect | 34 | 66% | DECREASE | -0.52183883 |
| rs1390270595 | TAC ⇒ TGC | Y51C | Disease | 2 | effect | 39 | 66% | DECREASE | -0.83530596 |
| rs1397132797 | CTG ⇒ CCG | L196P | Disease | 8 | effect | 58 | 75% | DECREASE | -2.0384073 |
| rs1414848134 | GAC ⇒ GTC | D54V | Disease | 5 | effect | 75 | 85% | DECREASE | -0.37383825 |
| rs1430565057 | CCT ⇒ CTT | P234L | Disease | 7 | effect | 81 | 91% | INCREASE | 0.3342289 |
| rs1472538844 | CCC ⇒ CGC | P209R | Disease | 3 | effect | 46 | 71% | DECREASE | -1.0509858 |
| rs1475659109 | CCC ⇒ CTC | P39L | Disease | 5 | effect | 29 | 63% | DECREASE | -0.20370663 |
| rs555347515 | ATG ⇒ AAG | M29K | Disease | 6 | effect | 25 | 63% | DECREASE | -1.7776487 |
| rs556645753 | GAC ⇒ GGC | D153G | Disease | 2 | effect | 17 | 59% | DECREASE | -2.384922 |
| rs565858069 | GAC ⇒ CAC | D130H | Disease | 5 | effect | 2 | 53% | DECREASE | -1.0708696 |
| rs754527717 | GAT ⇒ GGT | D244G | Disease | 2 | effect | 7 | 53% | DECREASE | -1.7605711 |
| rs1161818149 | CTG ⇒ CAG | L105Q | Disease | 3 | effect | 70 | 85% | DECREASE | -1.8766335 |
| CTG ⇒ CCG | L105P | Disease | 6 | effect | 76 | 85% | DECREASE | -2.1510154 | |
Evolutionary conservation pattern of amino acids with solvent accessibility in HLA-G1 by ConSurf server
| Isoform 1 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| conservation score | exposed or buried | prediction | conservation score | exposed or buried | prediction | conservation score | exposed or buried | prediction | conservation score | exposed or buried | prediction |
| 1 (variable) | buried | - | 1 (variable) | buried | - | 9 (conserved) | buried | structural | 7 (conserved) | exposed | |
| 6 (average) | buried | - | 9 (conserved) | buried | structural | 9 (conserved) | buried | structural | 9 (conserved) | exposed | functional |
| 9 (conserved) | exposed | functional | 8 (conserved) | exposed | functional | 7 (conserved) | exposed | - | 9 (conserved) | exposed | functional |
| 9 (conserved) | exposed | functional | 9 (conserved) | buried | structural | 9 (conserved) | buried | structural | 9 (conserved) | buried | structural |
| 9 (conserved) | buried | structural | 9 (conserved) | exposed | functional | 9 (conserved) | buried | structural | 9 (conserved) | buried | structural |
| 8 (conserved) | exposed | functional | 9 (conserved) | exposed | functional | 9 (conserved) | buried | structural | 9 (conserved) | buried | structural |
| 7 (conserved) | exposed | - | 9 (conserved) | buried | structural | 9 (conserved) | exposed | functional | 6 (average) | buried | |
| 9 (conserved) | buried | structural | 9 (conserved) | exposed | functional | 9 (conserved) | buried | structural | 8 (conserved) | exposed | functional |
Conservation score has a range of 1.0 to 9.0. Score 9 represents the most conserved and 1 represents the very variable amino acid. An amino acid, if is preserved and exposed, is a functional residue and if is preserved and buried, is a structural residue
Fig. 4Consurf analysis of HLA-G1. The degree of conservation of amino acids was shown in the colouring scheme. The color intensity increases based on amino acids conservation grades e.g. turquoise indicates variable sites; white indicates average sites; maroon indicates evolutionarily conserved sites. The most deleterious predicted SNPs are marked below the sequence as red arrows. e is the exposed residue. b is the buried residue. f is an estimated functional residue (highly conserved and exposed). s is an estimated structural residue (highly conserved and buried)
Prediction of functional effects of the most deleterious SNPs on the HLA-G1 by MutPred
| Isoform 1 (ID: 79bb0a85-d537-4be0-bff8-d0fdb06b5211) | |||||
|---|---|---|---|---|---|
| Substitution | Mutpred score (>0.50 is considered pathogenic) | Molecular mechanism with | Probability | prediction | |
| 0.823 | Altered Metal binding | 0.27 | 0.02 | confident hypotheses | |
| 0.26 | 1.0e-03 | ||||
| Altered Ordered interface | 0.25 | 0.03 | confident hypotheses | ||
| 0.665 | Altered Transmembrane protein | 0.28 | 4.8e-04 | actionable hypotheses | |
| Loss of Strand | 0.28 | 9.6e-03 | actionable hypotheses | ||
| Altered Metal binding | 0.27 | 0.02 | actionable hypotheses | ||
| Altered Ordered interface | 0.25 | 0.02 | actionable hypotheses | ||
| 0.644 | Altered Transmembrane protein | 0.13 | 0.02 | actionable hypotheses | |
| 0.767 | 0.32 | 1.8e-03 | |||
| 0.25 | 1.3e-03 | ||||
| 0.792 | 0.29 | 5.0e-03 | |||
| 0.21 | 1.2e-03 | ||||
| Altered Stability | 0.20 | 0.01 | confident hypotheses | ||
| 0.16 | 3.5e-03 | ||||
| 0.717 | Altered Ordered interface | 0.32 | 3.6e-03 | actionable hypotheses | |
| Gain of Relative solvent accessibility | 0.29 | 0.01 | actionable hypotheses | ||
| Altered Disordered interface | 0.28 | 0.03 | actionable hypotheses | ||
| Loss of Allosteric site at W157 | 0.28 | 7.4e-03 | actionable hypotheses | ||
| Altered Metal binding | 0.27 | 4.4e-03 | actionable hypotheses | ||
| Altered Transmembrane protein | 0.27 | 6.6e-04 | actionable hypotheses | ||
| Loss of Helix | 0.27 | 0.05 | actionable hypotheses | ||
| Altered Coiled coil | 0.10 | 0.04 | actionable hypotheses | ||
| 0.681 | Altered Metal binding | 0.74 | 1.1e-03 | actionable hypotheses | |
| Altered Disordered interface | 0.61 | 1.7e-04 | actionable hypotheses | ||
| Altered Ordered interface | 0.50 | 1.7e-04 | actionable hypotheses | ||
| Altered Transmembrane protein | 0.29 | 2.1e-04 | actionable hypotheses | ||
| Gain of Relative solvent accessibility | 0.27 | 0.02 | actionable hypotheses | ||
| Loss of Acetylation at K145 | 0.20 | 0.04 | actionable hypotheses | ||
| Loss of Methylation at K145 | 0.17 | 0.01 | actionable hypotheses | ||
| Loss of Ubiquitylation at K145 | 0.16 | 0.04 | actionable hypotheses | ||
| Gain of Disulfide linkage at Y142 | 0.09 | 0.05 | actionable hypotheses | ||
| Loss of Sulfation at Y147 | 0.09 | 3.5e-03 | actionable hypotheses | ||
| 0.658 | Altered Disordered interface | 0.33 | 0.01 | actionable hypotheses | |
| Altered Ordered interface | 0.28 | 0.04 | actionable hypotheses | ||
| Altered Transmembrane protein | 0.26 | 1.1e-03 | actionable hypotheses | ||
| Loss of Strand | 0.26 | 0.04 | actionable hypotheses | ||
| Loss of Pyrrolidone carboxylic acid at Q242 | 0.06 | 0.02 | actionable hypotheses | ||
| 0.444 | Altered Ordered interface | 0.28 | 0.03 | - | |
| Gain of Relative solvent accessibility | 0.26 | 0.03 | |||
| Loss of Methylation at K267 | 0.23 | 3.8e-03 | |||
| Gain of Acetylation at K267 | 0.22 | 0.02 | |||
| Loss of Pyrrolidone carboxylic acid at Q266 | 0.21 | 1.8e-03 | |||
| Altered Metal binding | 0.20 | 0.03 | |||
| Gain of Catalytic site at D262 | 0.16 | 0.02 | |||
| Altered Transmembrane protein | 0.15 | 0.01 | |||
| Gain of Proteolytic cleavage at D262 | 0.14 | 0.02 | |||
| 0.746 | Altered Ordered interface | 0.39 | 1.1e-03 | actionable hypotheses | |
| Altered Disordered interface =) | 0.38 | 6.6e-03 | actionable hypotheses | ||
| Altered Metal binding | 0.37 | 1.7e-03 | actionable hypotheses actionable | ||
| Altered Transmembrane protein | 0.19 | 6.6e-03 | hypotheses | ||
| Loss of Proteolytic cleavage at D53 | 0.12 | 0.03 | actionable hypotheses | ||
| Gain of Pyrrolidone carboxylic acid at Q56 | 0.09 | 0.01 | actionable hypotheses | ||
| Gain of Sulfation at D53 | 0.07 | 4.4e-03 | actionable hypotheses | ||
| 0.822 | 0.36 | 2.1e-03 | |||
| Altered Transmembrane protein | 0.12 | 0.03 | confident hypotheses | ||
| 0.87 | 0.42 | 3.2e-03 | |||
| 0.39 | 4.0e-04 | ||||
| 0.34 | 9.6e-03 | ||||
| 0.31 | 1.2e-04 | ||||
| Loss of Helix | 0.28 | 0.03 | confident hypotheses | ||
| 0.888 | 0.37 | 7.8e-03 | |||
| 0.34 | 0.01 | ||||
| 0.28 | 4.3e-03 | ||||
| Loss of Helix | 0.27 | 0.04 | confident hypotheses | ||
| 0.26 | 9.6e-04 | ||||
| 0.735 | Altered Disordered interface | 0.36 | 7.6e-03 | actionable hypotheses | |
| Gain of Intrinsic disorder | 0.34 | 0.02 | actionable hypotheses | ||
| Altered Transmembrane protein | 0.31 | 1.1e-04 | actionable hypotheses | ||
| Loss of Helix | 0.31 | 4.8e-03 | actionable hypotheses | ||
| Altered DNA binding | 0.25 | 8.9e-03 | actionable hypotheses | ||
| Altered Stability | 0.21 | 0.01 | actionable hypotheses | ||
| Loss of Proteolytic cleavage at R99 | 0.13 | 0.02 | actionable hypotheses | ||
| 0.667 | Altered Metal binding | 0.78 | 8.2e-04 | actionable hypotheses | |
| Altered Ordered interface | 0.44 | 5.4e-04 | actionable hypotheses | ||
| Altered Disordered interface | 0.35 | 8.9e-03 | actionable hypotheses | ||
| Altered Transmembrane protein | 0.31 | 1.1e-04 | actionable hypotheses | ||
| Gain of Relative solvent accessibility | 0.25 | 0.03 | actionable hypotheses | ||
| Gain of Acetylation at K145 | 0.20 | 0.04 | actionable hypotheses | ||
| Loss of Methylation at K145 | 0.17 | 0.01 | actionable hypotheses | ||
| Altered Stability | 0.17 | 0.02 | actionable hypotheses | ||
| Loss of Ubiquitylation at K145 ( | 0.15 | 0.05 | actionable hypotheses | ||
| Altered Coiled coil | 0.10 | 0.04 | actionable hypotheses | ||
| Loss of Sulfation at Y147 | 0.09 | 3.5e-03 | actionable hypotheses | ||
| 0.795 | Altered Disordered interface | 0.29 | 0.03 | confident hypotheses | |
| Altered Ordered interface | 0.24 | 0.03 | confident hypotheses | ||
| Altered DNA binding | 0.17 | 0.03 | confident hypotheses | ||
| Altered Transmembrane protein | 0.09 | 0.05 | confident hypotheses | ||
| 0.607 | Altered Metal binding | 0.47 | 5.9e-03 | actionable hypotheses | |
| Altered Ordered interface | 0.28 | 0.04 | actionable hypotheses | ||
| Loss of Loop | 0.27 | 0.02 | actionable hypotheses | ||
| Altered Transmembrane protein | 0.20 | 5.0e-03 | actionable hypotheses | ||
| Gain of Catalytic site at D262 | 0.13 | 0.03 | actionable hypotheses | ||
| Loss of Proteolytic cleavage at D262 | 0.13 | 0.03 | actionable hypotheses | ||
| 0.936 | 0.37 | 1.8e-03 | |||
| 0.36 | 1.5e-05 | ||||
| 0.33 | 3.3e-03 | ||||
| Altered Disordered interface | 0.30 | 0.02 | confident hypotheses | ||
| 0.30 | 3.7e-03 | ||||
| 0.28 | 3.8e-03 | ||||
| Altered Coiled coil | 0.27 | 0.01 | confident hypotheses | ||
| 0.843 | 0.34 | 2.4e-05 | |||
| Altered Metal binding | 0.29 | 0.02 | confident hypotheses | ||
| Gain of Relative solvent accessibility | 0.28 | 0.02 | confident hypotheses | ||
| 0.27 | 9.8e-03 | ||||
| 0.683 | Loss of Helix | 0.30 | 9.0e-03 | actionable hypotheses | |
| Altered Transmembrane protein | 0.29 | 3.0e-04 | actionable hypotheses | ||
| Altered DNA binding | 0.25 | 6.7e-03 | actionable hypotheses | ||
| Gain of Ubiquitylation at K92 | 0.15 | 0.04 | actionable hypotheses | ||
| Gain of Proteolytic cleavage at R99 | 0.13 | 0.02 | actionable hypotheses | ||
| Loss of Pyrrolidone carboxylic acid at Q96 | 0.10 | 0.01 | actionable hypotheses | ||
| 0.527 | Altered Ordered interface | 0.27 | 8.6e-03 | actionable hypotheses | |
| 0.649 | Altered Metal binding | 0.38 | 1.5e-03 | actionable hypotheses | |
| Altered Transmembrane protein | 0.28 | 3.8e-04 | actionable hypotheses | ||
| Altered Ordered interface | 0.28 | 0.04 | actionable hypotheses | ||
| Altered Disordered interface | 0.28 | 0.03 | actionable hypotheses | ||
| Gain of Relative solvent accessibility | 0.26 | 0.03 | actionable hypotheses | ||
| Loss of Acetylation at K145 | 0.19 | 0.05 | actionable hypotheses | ||
| Loss of Methylation at K145 | 0.16 | 0.01 | actionable hypotheses | ||
| Loss of Ubiquitylation at K145 | 0.15 | 0.04 | actionable hypotheses | ||
| Loss of Sulfation at Y147 | 0.09 | 3.4e-03 | actionable hypotheses | ||
| 0.738 | Altered Metal binding | 0.43 | 7.0e-03 | actionable hypotheses | |
| Altered Transmembrane protein | 0.32 | 7.8e-05 | actionable hypotheses | ||
| Altered Disordered interface | 0.29 | 0.03 | actionable hypotheses | ||
| Altered Ordered interface | 0.27 | 7.0e-03 | actionable hypotheses | ||
| Loss of Relative solvent accessibility | 0.26 | 0.03 | actionable hypotheses | ||
| Loss of Acetylation at K145 | 0.19 | 0.05 | actionable hypotheses | ||
| Loss of Methylation at K145 | 0.17 | 0.01 | actionable hypotheses | ||
| Loss of Ubiquitylation at K145 | 0.16 | 0.03 | actionable hypotheses | ||
| Loss of Sulfation at Y147 | 0.09 | 3.3e-03 | actionable hypotheses | ||
| 0.617 | Gain of Intrinsic disorder | 0.34 | 0.02 | actionable hypotheses | |
| Altered Ordered interface | 0.29 | 0.03 | actionable hypotheses | ||
| Loss of Helix | 0.27 | 0.05 | actionable hypotheses | ||
| 0.715 | Altered Disordered interface | 0.60 | 1.9e-04 | actionable hypotheses | |
| Altered Metal binding | 0.53 | 4.1e-03 | actionable hypotheses | ||
| Altered Ordered interface | 0.30 | 4.6e-03 | actionable hypotheses | ||
| Loss of Strand | 0.27 | 0.02 | actionable hypotheses | ||
| Altered Transmembrane protein | 0.20 | 5.0e-03 | actionable hypotheses | ||
| Loss of Proteolytic cleavage at D53 | 0.12 | 0.03 | actionable hypotheses | ||
| Altered Stability | 0.12 | 0.03 | actionable hypotheses | ||
| Gain of Pyrrolidone carboxylic acid at Q56 | 0.08 | 0.02 | actionable hypotheses | ||
| Loss of Sulfation at Y51 | 0.03 | 0.02 | actionable hypotheses | ||
| 0.884 | Altered Disordered interface | 0.34 | 0.01 | confident hypotheses | |
| 0.27 | 9.0e-03 | ||||
| Altered DNA binding | 0.16 | 0.04 | confident hypotheses | ||
| Altered Stability | 0.14 | 0.02 | confident hypotheses | ||
| 0.718 | Altered Metal binding | 0.55 | 3.1e-04 | actionable hypotheses | |
| Altered Disordered interface | 0.40 | 4.2e-03 | actionable hypotheses | ||
| Altered Ordered interface | 0.25 | 0.02 | actionable hypotheses | ||
| Altered Transmembrane protein | 0.14 | 0.02 | actionable hypotheses | ||
| Loss of Proteolytic cleavage at D53 | 0.12 | 0.03 | actionable hypotheses | ||
| Gain of Pyrrolidone carboxylic acid at Q56 | 0.09 | 0.01 | actionable hypotheses | ||
| Loss of Sulfation at Y51 | 0.03 | 0.02 | actionable hypotheses | ||
| 0.809 | 0.33 | 1.5e-03 | |||
| Altered Disordered interface | 0.30 | 0.03 | confident hypotheses | ||
| 0.29 | 2.0e-04 | ||||
| Loss of Strand | 0.28 | 0.01 | confident hypotheses | ||
| 0.659 | Altered Disordered interface | 0.27 | 0.04 | actionable hypotheses | |
| Loss of B-factor | 0.26 | 0.04 | actionable hypotheses | ||
| Altered Transmembrane protein | 0.24 | 1.6e-03 | actionable hypotheses | ||
| Altered DNA binding | 0.23 | 9.6e-03 | actionable hypotheses | ||
| Gain of Proteolytic cleavage at R38 | 0.14 | 0.02 | actionable hypotheses | ||
| 0.720 | Altered Ordered interface | 0.26 | 0.02 | actionable hypotheses | |
| Loss of Proteolytic cleavage at R30 | 0.20 | 2.6e-03 | actionable hypotheses | ||
| Altered Stability | 0.13 | 0.03 | actionable hypotheses | ||
| Altered Transmembrane protein | 0.12 | 0.03 | actionable hypotheses | ||
| Altered Metal binding | 0.11 | 7.9e-03 | actionable hypotheses | ||
| 0.853 | 0.45 | 1.6e-04 | |||
| 0.35 | 9.1e-03 | ||||
| 0.30 | 8.2e-03 | ||||
| 0.30 | 3.1e-03 | ||||
| 0.28 | 4.6e-04 | ||||
| Altered Ordered interface | 0.26 | 0.01 | confident hypotheses | ||
| 0.26 | 7.0e-03 | ||||
| Altered Stability | 0.19 | 0.01 | confident hypotheses | ||
| Altered Coiled coil | 0.10 | 0.04 | confident hypotheses | ||
| 0.724 | Altered Transmembrane protein | 0.30 | 1.9e-04 | actionable hypotheses | |
| Altered Disordered interface | 0.28 | 0.03 | actionable hypotheses | ||
| Altered Metal binding | 0.25 | 0.03 | actionable hypotheses | ||
| Loss of Relative solvent accessibility | 0.25 | 0.04 | actionable hypotheses | ||
| Altered Ordered interface | 0.24 | 0.04 | actionable hypotheses | ||
| Gain of Disulfide linkage at C125 | 0.10 | 0.05 | actionable hypotheses | ||
| Gain of Catalytic site at D126 | 0.08 | 0.05 | actionable hypotheses | ||
| 0.705 | Altered Ordered interface | 0.30 | 0.02 | actionable hypotheses | |
| Altered Disordered interface | 0.28 | 0.04 | actionable hypotheses | ||
| Gain of Strand | 0.27 | 0.02 | actionable hypotheses | ||
| Altered Transmembrane protein | 0.26 | 8.2e-04 | actionable hypotheses | ||
| Altered Metal binding | 0.18 | 0.03 | actionable hypotheses | ||
| Gain of Pyrrolidone carboxylic acid at Q248 | 0.15 | 4.6e-03 | actionable hypotheses | ||
| Loss of Proteolytic cleavage at R243 | 0.12 | 0.03 | actionable hypotheses | ||
| Loss of Catalytic site at R243 | 0.09 | 0.04 | actionable hypotheses | ||
| 0.507 | Altered Disordered interface | 0.32 | 0.01 | actionable hypotheses | |
| Gain of Intrinsic disorder | 0.30 | 0.05 | actionable hypotheses | ||
| Altered Transmembrane protein | 0.29 | 2.1e-04 | actionable hypotheses | ||
| Altered Ordered interface | 0.26 | 0.01 | actionable hypotheses | ||
| Altered DNA binding | 0.16 | 0.04 | actionable hypotheses | ||
| Altered Stability | 0.15 | 0.02 | actionable hypotheses | ||
| Loss of N-linked glycosylation at N110 | 0.05 | 0.02 | actionable hypotheses | ||
| 0.702 | Altered Disordered interface | 0.33 | 0.01 | actionable hypotheses | |
| Loss of Helix | 0.29 | 0.01 | actionable hypotheses | ||
| Altered Transmembrane protein | 0.28 | 3.7e-04 | actionable hypotheses | ||
| Altered Ordered interface | 0.26 | 0.01 | actionable hypotheses | ||
| Altered Stability | 0.20 | 0.01 | actionable hypotheses | ||
| Altered DNA binding | 0.16 | 0.04 | actionable hypotheses | ||
| Gain of N-linked glycosylation at N110 | 0.05 | 0.02 | actionable hypotheses | ||
The predictions which are very confident hypotheses shown in bold font
Table of HLA-G UTR SNPs with functional importance that were predicted by UTRscan tool
| SNP ID | Nucleotide change | UTR position | Functional element change |
|---|---|---|---|
| rs182801644 | C/T | 5′ UTR | no pattern → uORF |
| rs771111444 | C/G | 5′ UTR | no pattern → IRES no pattern → uORF |
Prediction results of PolymiRTS database
| dbSNP ID | miR ID | Conservation | miRSite | FunctionClass |
|---|---|---|---|---|
| rs1707 | hsa-miR-5702 | 2 | CTGACT | C |
| hsa-miR-583 | 3 | ctgact | C | |
| rs17179101 | hsa-miR-4417 | 2 | AGCCCA | D |
| hsa-miR-4651 | 5 | agcCCA | D | |
| hsa-miR-541-3p | 2 | aGCCCA | D | |
| hsa-miR-608 | 2 | agcCCA | D | |
| hsa-miR-654-5p | 2 | aGCCCA | D | |
| hsa-miR-6756-5p | 2 | agCCCA | D | |
| hsa-miR-6766-5p | 2 | agCCCA | D | |
| hsa-miR-6782-5p | 3 | agccCA | D | |
| hsa-miR-1587 | 2 | AGCCCA | C | |
| hsa-miR-296-3p | 6 | agccCA | C | |
| hsa-miR-3147 | 2 | aGCCCA | C | |
| hsa-miR-3620-5p | 2 | AGCCCA | C | |
| hsa-miR-4674 | 2 | AGCCCA | C | |
| hsa-miR-6823-5p | 3 | agcccA | C | |
| hsa-miR-92a-1-5p | 2 | agCCCA | C | |
| rs180827037 | hsa-miR-875-3p | 5 | tttcct | C |
| rs138249160 | hsa-miR-25-5p | 2 | tCTCCG | C |
| hsa-miR-6087 | 3 | tctCCG | C | |
| rs1063320 | hsa-miR-3619-3p | 3 | tgTGGT | C |
| hsa-miR-4776-5p | 3 | tgTGGT | C | |
| hsa-miR-4800-5p | 3 | tgtGGT | C | |
| hsa-miR-767-5p | 3 | tgTGGT | D |
In miRsite, sequences of the miRNA sites were shown. The capital letters show bases complementary to the seed region and SNPs were shown in bold font.
Fig. 5Protein–protein interaction network of HLAG with 10 partners
Fig. 6The correlation of deregulation of HLA-G gene and overall survival rate of the cancer patients was evaluated using Kaplan-Meier plotter
The correlation of deregulation of HLA-G gene and overall survival rate of the cancer patients as reported by previous studies in comparison with our results
| Type of cancer | Results found in our study | Results found in some previous studies | Controversy | Reference |
|---|---|---|---|---|
| Breast Cancer | HLA-G gene in breast cancer had a hazard ratio (HR) = 0.85 (95%CI, 0.69 − 1.06) and log-rank | In the whole cohort of patients, HLA-G showed no statistically significant difference in outcome between expression versus no expression for overall survival ( | No | [ |
| Breast cancer patients with positive HLA-G expression had a lower survival rate in comparison with negative HLA-G expression patients ( | Yes | [ | ||
| HLA-G upregulated expression was confirmed in breast cancer. HLA-G was associated with both improved relapse-free survival and overall survival. | Yes | [ | ||
| The expression of HLA-G was significantly higher in invasive ductal breast cancer patients with shorter survival time ( | Yes | [ | ||
| Breast cancer patients with HLA-G-positive tumor cells had shorter disease-free survival, though not significantly ( | No | [ | ||
| Ovarian Cancer | The relation between the high expression of HLA-G gene and more survival rate was statistically significant (less number of patients at risk) (HR = 0.81 (95%CI, 0.71 − 0.93) and log-rank | Ovarian cancer patients with HLA-G expression >17% showed poor survival than those with HLA-G expression <17% group with a | Yes | [ |
| The HLA-G5/-G6 was expressed in 79.7% (94/118) of ovarian cancer lesions. lesion HLA-G5/-G6 expression was unrelated to clinicoparameters including histological type, patient age, FIGO stages and patient survival. | Yes | [ | ||
| Survival was prolonged when ovarian tumors expressed HLA-G ( | No | [ | ||
| The Kaplan-Meier analysis demonstrated no significant association between survival and HLA-G expression status in ovarian carcinoma patients. | Yes | [ | ||
| Lung cancer | HLA-G gene in lung cancer had a HR = 1.21 (95%CI, 1.07 − 1.38) and log-rank | The Higher sHLA-G level above the median (≥50 U/ml) in patients is associated with statistically significant shorter survival time in comparison to the lower sHLA-G expression ( | No | [ |
| sHLA-G expression was observed in 34.0% (45/131) of the NSCLC lesions, which was unrelated to patient survival. | Yes | [ | ||
| Plasma sHLA-G above the median level (≥median, 32.0 U/ml) in NSCLC patients is strongly associated with shorter survival time ( | No | [ | ||
| Patients with sHLA-G <40 ng/ml ( | No | [ | ||
| Patients with HLA-G positive tumors had a significantly shorter survival time than those with tumors that were HLA-G negative ( | No | [ | ||
| Survival analyses were shown that the HLA class I loss was correlated to recurrence-free survival time. | No | [ | ||
| Gastric carcinoma patients with HLA-G positive tumors had a significantly shorter survival time than those patients with tumors that were HLA-G negative ( | No | [ | ||
| Gastric cancer | HLA-G gene in gastric cancer had a HR = 1.3 (95%CI, 1.09 − 1.54) and log-rank | Kaplan-Meier analyses indicated that patients with HLA-G-positive gastric cancer had a poorer prognosis than those with HLA-G negative gastric cancer ( | No | [ |
| The overall median survival was worse in gastric adenocarcinoma patients with HLA-G-positive tumors compared to those with HLA-G-negative tumors ( | No | [ | ||
| Kaplan–Meier analysis showed that gastric cancer patients with HLA-G expression had a significantly poorer overall survival than those without HLA-G expression at 5 years after the operation. | No | [ | ||
| The 5-year survival rate of gastric cancer patients in the HLA-G-positive group was significantly higher than the HLA-G-negative group. | Yes | [ |